ARIAD Pharmaceuticals (ARIA) : 4 Wall Street analysts covering ARIAD Pharmaceuticals (ARIA) believe that the average level the stock could reach for the short term is $11. The maximum price target given is $13 and the minimum target for short term is around $9, hence the standard deviation is calculated at $1.83.
ARIAD Pharmaceuticals (ARIA) : 4 analysts are covering ARIAD Pharmaceuticals (ARIA) and their average rating on the stock is 2, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock.
Also, Barclays maintains its rating on ARIAD Pharmaceuticals (NASDAQ:ARIA). The global brokerage major raises the current price target from $8 per share to $9 per share. Analysts at the Barclays have a current rating of Underweight on the shares. The rating by the firm was issued on July 29, 2016.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $10.33 on Thursday but the bulls could not build on the opening and the stock topped out at $10.37 for the day. The stock traded down to $10.06 during the day, due to lack of any buying support eventually closed down at $10.19 with a loss of -1.45% for the day. The stock had closed at $10.34 on the previous day. The total traded volume was 2,549,575 shares.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).